Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.
Er Chen, MPP
Advertisement
Articles by Er Chen, MPP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5